Colchicine as a treatment option for inherited epidermolysis bullosa
Epidermolysis bullosa (EB) is a rare inherited multisystem disorder. Colchicine is classified as an antigout and an anti-inflammatory drug. Currently, treatment options for EB are limited and focused on symptom management; there are no approved systemic treatments available. Here, we report three patients who were treated with colchicine to ameliorate EB wounds and systemic inflammation.
Authors
- Dedee Frances Murrell (ORCID: https://orcid.org/0000-0003-2971-0199)
- Ben Koszegi (ORCID: https://orcid.org/0000-0002-5279-782X)
- Sera Sarsam (ORCID: https://orcid.org/0000-0001-7134-9726)
Institutions
- UNSW Sydney (AU)
- St George Hospital (AU)
- St. George Hospital (IN)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1093/ced/llaf016
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00